Company Overview - Dynamix Corporation is a publicly-traded special purpose acquisition company (SPAC) incorporated in the Cayman Islands, focused on mergers and business combinations [6] - The company is led by experienced executives including CEO Andrejka Bernatova and CFO Nader Daylami [6] Business Combination - Dynamix Corporation announced a business combination with The Ether Reserve, LLC to form The Ether Machine, a strategic ether generation company [2][4] - The Ether Machine aims to deliver long-term, risk-adjusted yield through staking, restaking, and decentralized finance, with a focus on growing ether concentration per share [2][5] Ticker Symbol Change - The ticker symbols for Dynamix's common stock, units, and warrants will change from "DYNX," "DYNXU," and "DYNXW" to "ETHM," "ETHMU," and "ETHMW," respectively, effective August 27, 2025 [1][4] - This change is intended to facilitate a smooth transition for shareholders ahead of the business combination [3] Strategic Goals - The Ether Machine is expected to have one of the largest on-chain ETH positions of any public entity and will focus on generating and optimizing ETH-denominated returns [5] - The company plans to provide turnkey infrastructure solutions for enterprises and Ethereum-native builders [5] Approval and Timeline - The business combination has been unanimously approved by the boards of directors of both companies and is expected to close by the fourth quarter of 2025, pending shareholder approval [4]

Core Points - Plus Therapeutics, Inc. has confirmed compliance with Nasdaq Listing Rule 5550(b), meeting both the Market Value of Listing Securities (MVLS) standard of at least $35 million and the stockholders' equity threshold of at least $2.5 million [1][2] - Nasdaq has granted Plus Therapeutics an extension until November 12, 2025, to regain compliance with the $1.00 bid price rule, previously set for September 8, 2025 [2] - The company is under a one-year monitoring period for the Equity Standard, which will last until August 22, 2026, during which it must maintain compliance to avoid delisting [3] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for central nervous system cancers [4] - The company employs advanced technologies combining image-guided local beta radiation and targeted drug delivery, with key programs targeting leptomeningeal metastases and recurrent glioblastoma [4] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

Core Viewpoint - Orchestra BioMed Holdings, Inc. announced favorable hemodynamic effects of AVIM therapy for patients with uncontrolled hypertension, as published in the Journal of the American College of Cardiology: Clinical Electrophysiology [1][2][3] Group 1: AVIM Therapy Findings - AVIM therapy demonstrated statistically significant reductions in systolic blood pressure (SBP) by an average of 17.1 mmHg (RV pacing) and 19.2 mmHg (CSP), compared to 1.7 mmHg with standard pacing [6] - The therapy improved left ventricular hemodynamics, with end-diastolic volume decreasing by 12.6 mL (RV) and 18.6 mL (CSP), and end-systolic volume decreasing by 11.0 mL (RV) and 14.1 mL (CSP) [6] - AVIM therapy also significantly reduced cardiac workload, with stroke work decreasing by 1,596 mL (RV) and 1,870 mL (CSP), compared to 42 mL with standard pacing [6] Group 2: Clinical Implications - The publication of the data in a peer-reviewed journal reinforces the therapeutic rationale behind AVIM therapy, highlighting its potential to deliver differentiated clinical benefits for patients with uncontrolled hypertension [3][7] - AVIM therapy has received FDA Breakthrough Device Designation for treating uncontrolled hypertension in patients with increased cardiovascular risk, estimated to be over 7.7 million patients in the U.S. [5][10] - The strategic collaboration between Orchestra BioMed and Medtronic aims to develop AVIM therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients, a population of over 750,000 patients annually [5][10] Group 3: Research and Development - The BACKBEAT global pivotal study is currently evaluating the safety and efficacy of AVIM therapy in patients with systolic blood pressure above target despite anti-hypertensive medication [10] - The MODERATO II study showed that patients treated with AVIM therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure and 12.3 mmHg in office systolic blood pressure at six months compared to control patients [10] - AVIM therapy is compatible with standard dual-chamber pacemakers and aims to substantially and persistently lower blood pressure [10]

Group 1 - The Board of Trustees of Ellsworth Growth and Income Fund Ltd. has increased the quarterly distribution to $0.19 per share, a 20% increase from the previous $0.16 per share [1] - The new distribution will commence in December 2025, raising the annualized distribution rate from $0.64 to $0.76 per share [1] - The increase in distribution reflects the Fund's strong NAV total return of 18% year to date [1] Group 2 - Ellsworth Growth and Income Fund Ltd. is a diversified, closed-end management investment company with total net assets of $199 million [2] - The Fund primarily invests in convertible securities and common stock, aiming to provide income and potential capital appreciation [2] - Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc., manages the Fund [2]

RYE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- The Board of Trustees of GAMCO Natural Resources, Gold & Income Trust (NYSE: GNT) (the “Fund”) authorized a 25% increase in the monthly cash distribution to $0.05 per share from $0.04 per share, beginning in October 2025. The increase reflects the strength of the Fund’s NAV total return of 28% year to date. Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. For more information regarding the F ...

Group 1 - Curanex Pharmaceuticals Inc. has priced its initial public offering (IPO) of 3,750,000 shares at $4.00 per share, aiming for gross proceeds of $15 million [1] - The IPO is expected to close on August 27, 2025, and shares will begin trading on the Nasdaq Capital Market under the ticker symbol "CURX" [1] - Underwriters have an option to purchase an additional 562,500 shares within 45 days of the offering's close [1] Group 2 - Proceeds from the offering will be used for the development of the lead product candidate, Phyto-N, for ulcerative colitis, including FDA-required studies and IND application preparation [2] - Curanex Pharmaceuticals is focused on developing botanical drugs for inflammatory diseases, with Phyto-N being a botanical extract with proven anti-inflammatory properties [7][8] - Phyto-N has been validated in animal models for six inflammatory diseases, with the primary indication being moderate to severe ulcerative colitis [8] Group 3 - Dominari Securities LLC is the lead underwriter for the offering, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters [3] - A registration statement for the offering was filed with the SEC and declared effective on August 12, 2025 [4] - The final prospectus related to the offering will be available on the SEC's website [4][5]

RESTON, Va., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and program management firm, announced it will participate in D.A. Davidson’s 24th Annual Diversified Industrials & Services Conference held September 17-19. The conference will be at The Four Seasons Hotel in Nashville, Tennessee. About Bowman Consulting Group Ltd.Headquartered in Reston, Virginia, Bowman is a national engineering services firm delivering infrastructure, technology an ...

Core Insights - DraftKings Inc. is launching a monthlong campaign for Responsible Gaming Education Month (RGEM) to promote responsible gaming through a sweepstakes offering NFL tickets and a trip to Super Bowl LX [1][2] - The campaign encourages customer engagement with responsible gaming tools like My Budget Builder and My Stat Sheet, aiming to foster a more informed gaming culture [2][4] Group 1: Campaign Details - The sweepstakes will run from August 26 to September 8, allowing customers to win NFL regular season tickets by using My Budget Builder [2] - Each week will introduce new responsible gaming engagement methods, with additional ticket giveaways and a grand prize trip to Super Bowl LX for using My Stat Sheet [2][3] Group 2: Tool Highlights - My Budget Builder, launched in June 2025, builds on the success of My Stat Sheet, which has been utilized by approximately 3.4 million customers to track their gaming activity [3] - DraftKings emphasizes the integration of responsible gaming tools throughout the customer journey, reinforcing its commitment to responsible play [4] Group 3: Company Commitment - DraftKings is dedicated to providing a fun and responsible gaming experience, sharing a new Code of Responsible Play with customers to promote responsible behavior [4] - The company aims to maintain responsible gaming as a core aspect of its product design and long-term strategy as it continues to grow [4][6]

Company Announcement - FuelCell Energy, Inc. will release its third quarter 2025 results on September 9, 2025, before the stock market opens [1] - Following the results announcement, the company will host a conference call with investors at 10:00 a.m. Eastern Time on the same day [1] Conference Call Details - The conference call will be accessible via webcast on the company's website or by telephone [1] - A replay of the conference call will be available approximately two hours after the conclusion of the call on the company's Investors' page [2] Company Overview - FuelCell Energy provides clean and reliable energy solutions that enable customers to access power quickly and manage emissions [3] - The company's systems are efficient, scalable, and fuel-flexible, operating on natural gas, biofuels, or hydrogen, and provide steady baseload electricity [3] - With over 55 years of expertise and nearly 200 modules deployed, FuelCell Energy assists customers in achieving their energy goals [3]

Company Overview - Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases [1] - The company's lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist targeting MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD), and obesity [1] Investor Engagement - Management will participate in several upcoming investor conferences, including the Wells Fargo Healthcare Conference on September 5, 2025, and the H.C. Wainwright Global Investment Conference on September 9, 2025 [3] - The Morgan Stanley Global Healthcare Conference is scheduled for September 10, 2025, where a fireside chat will take place [3] - These events will include one-on-one meetings and webcasts accessible via the Altimmune website [3]